Arrowhead Research | ARWR - Gross Profit On Sales


Arrowhead Research reported $264.03M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
Anika Therapeutics USD 19.18M 3.6M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Heron Therapeutics USD 29.47M 3.17M Dec/2025
Incyte USD 1.17B 217.51M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Ligand Pharmaceuticals USD 48.45M 8.22M Mar/2026
Merck USD 10.85B 2.57B Dec/2025
Moderna USD -566M 792M Mar/2026
Nektar Therapeutics USD 21.81M 8.06M Dec/2025
Novartis USD 10.07B 184M Mar/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
TG Therapeutics USD 171.41M 16.98M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Xencor USD 21M 22.61M Sep/2025